Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4364MR)

This product GTTS-WQ4364MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4364MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12912MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ9524MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ497MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ10983MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ14755MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ456MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ8042MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ14029MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW